Karyopharm Therapeutics (KPTI) Other Gross PP&E Adjustments (2016 - 2025)
Historic Other Gross PP&E Adjustments for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to -$1.8 million.
- Karyopharm Therapeutics' Other Gross PP&E Adjustments rose 5755.17% to -$1.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.8 million, marking a year-over-year increase of 5755.17%. This contributed to the annual value of -$1.8 million for FY2025, which is 5755.17% up from last year.
- Karyopharm Therapeutics' Other Gross PP&E Adjustments amounted to -$1.8 million in Q4 2025, which was up 5755.17% from -$4.7 million recorded in Q3 2025.
- In the past 5 years, Karyopharm Therapeutics' Other Gross PP&E Adjustments registered a high of -$1.8 million during Q4 2025, and its lowest value of -$12.8 million during Q4 2021.
- Over the past 5 years, Karyopharm Therapeutics' median Other Gross PP&E Adjustments value was -$5.5 million (recorded in 2023), while the average stood at -$6.2 million.
- Data for Karyopharm Therapeutics' Other Gross PP&E Adjustments shows a peak YoY increase of 5755.17% (in 2025) and a maximum YoY decrease of 8097.45% (in 2025) over the last 5 years.
- Karyopharm Therapeutics' Other Gross PP&E Adjustments (Quarter) stood at -$12.8 million in 2021, then increased by 3.91% to -$12.3 million in 2022, then skyrocketed by 54.33% to -$5.6 million in 2023, then rose by 25.82% to -$4.2 million in 2024, then skyrocketed by 57.55% to -$1.8 million in 2025.
- Its Other Gross PP&E Adjustments was -$1.8 million in Q4 2025, compared to -$4.7 million in Q3 2025 and -$5.1 million in Q2 2025.